EWM
RXRX icon

Empirical Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Empirical Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-29,548
Closed -$226K – 510
2023
Q3 		$226K Buy
29,548
+16,128
+120% +$161K 0.01% 424
2023
Q2 		$100K Buy
+13,420
New +$93.9K ﹤0.01% 449

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Empirical Wealth Management's RXRX Position: Q4 2023 in Review

Empirical Wealth Management sold out of Recursion Pharmaceuticals (RXRX) in Q4 2023, closing a stake of 29,548 shares — an estimated $226K sold.

Empirical Wealth Management first reported a position in RXRX in Q2 2023 and held it in 2 quarters. The position peaked at $226K in Q3 2023. 199 funds tracked by Wall St. Rank hold RXRX as of Q4 2023.

  • Empirical Wealth Management reported no remaining Recursion Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Empirical Wealth Management sold 29,548 Recursion Pharmaceuticals shares in Q4 2023, an estimated $226K.
  • Empirical Wealth Management first reported a position in Recursion Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Empirical Wealth Management's Recursion Pharmaceuticals position peaked at $226K in Q3 2023.
  • 199 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2023.

Based on Empirical Wealth Management's 13F filing for Q4 2023, filed 6 Feb 2024.